Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.

To date, anti-tumor necrosis factor alfa (anti-TNF-a) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive...

ver descrição completa

Detalhes bibliográficos
Autores: Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J, AIRE-MB group
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:España
Recursos:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p7028
Acesso em linha:https://fisabio.portalinvestigacion.com/publicaciones/7028
Access Level:acceso abierto
Palavra-chave:ankylosing spondylitis, efficacy, etanercept, safety, spondyloarthritis
id ES_080c65340dad7cf9931a0cd1ee5ccd2c
oai_identifier_str oai:fisabio.fundanetsuite.com:p7028
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.Senabre-Gallego JMSantos-Ramírez CSantos-Soler GSalas-Heredia ESánchez-Barrioluengo MBarber XRosas JAIRE-MB groupankylosing spondylitis, efficacy, etanercept, safety, spondyloarthritisTo date, anti-tumor necrosis factor alfa (anti-TNF-a) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn's disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.DOVE MEDICAL PRESS LTD2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/7028Patient Preference and AdherenceISSN: 1177889Xreponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p70282026-06-11T12:45:17Z
dc.title.none.fl_str_mv Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
title Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
spellingShingle Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
Senabre-Gallego JM
ankylosing spondylitis, efficacy, etanercept, safety, spondyloarthritis
title_short Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
title_full Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
title_fullStr Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
title_full_unstemmed Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
title_sort Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.
dc.creator.none.fl_str_mv Senabre-Gallego JM
Santos-Ramírez C
Santos-Soler G
Salas-Heredia E
Sánchez-Barrioluengo M
Barber X
Rosas J
AIRE-MB group
author Senabre-Gallego JM
author_facet Senabre-Gallego JM
Santos-Ramírez C
Santos-Soler G
Salas-Heredia E
Sánchez-Barrioluengo M
Barber X
Rosas J
AIRE-MB group
author_role author
author2 Santos-Ramírez C
Santos-Soler G
Salas-Heredia E
Sánchez-Barrioluengo M
Barber X
Rosas J
AIRE-MB group
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ankylosing spondylitis, efficacy, etanercept, safety, spondyloarthritis
topic ankylosing spondylitis, efficacy, etanercept, safety, spondyloarthritis
description To date, anti-tumor necrosis factor alfa (anti-TNF-a) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept has demonstrated efficacy in the treatment of ankylosing spondylitis, with or without radiographic sacroiliitis, and other manifestations of the disease, including peripheral arthritis, enthesitis, and psoriasis. Etanercept is not efficacious in inflammatory bowel disease, and its efficacy in the treatment of uveitis appears to be lower than that of other anti-TNF drugs. Studies of etanercept confirmed regression of bone edema on magnetic resonance imaging of the spine and sacroiliac joint, but failed to reduce radiographic progression, as do the other anti-TNF drugs. It seems that a proportion of patients remain in disease remission when the etanercept dose is reduced or administration intervals are extended. Etanercept is generally well tolerated with an acceptable safety profile in the treatment of ankylosing spondylitis. The most common adverse effect of etanercept treatment is injection site reactions, which are generally self-limiting. Reactivation of tuberculosis, reactivation of hepatitis B virus infection, congestive heart failure, demyelinating neurologic disorders, hematologic disorders like aplastic anemia and pancytopenia, vasculitis, immunogenicity, and exacerbation or induction of psoriasis are class effects of all the anti-TNF drugs, and have been seen in patients with ankylosing spondylitis. However, etanercept is less likely to induce reactivation of tuberculosis than the other anti-TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn's disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.
publishDate 2013
dc.date.none.fl_str_mv 2013
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/7028
url https://fisabio.portalinvestigacion.com/publicaciones/7028
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv DOVE MEDICAL PRESS LTD
publisher.none.fl_str_mv DOVE MEDICAL PRESS LTD
dc.source.none.fl_str_mv Patient Preference and Adherence
ISSN: 1177889X
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403019974541312
score 15,81155

Registos relacionados